Hospital
Acadia General Hospital, INC.
Acadia General Hospital, INC. was paid $8.42M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoACADIA GENERAL HOSPITAL, INC.
CROWLEY, LA 70526
CROWLEY, LA 70526
33aNPI1669882940assigned 05/07/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.42M
24GClaims332,549
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#38 of 96
Median peer was paid$5.17M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,507 | $1.46M | |
| 2019 | 47,956 | $1.32M | |
| 2020 | 44,229 | $870K | |
| 2021 | 58,294 | $1.15M | |
| 2022 | 47,696 | $1.27M | |
| 2023 | 49,636 | $1.35M | |
| 2024incomplete | 34,231 | $984K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 21,917 | 20,384 | $2.17M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 23,750 | 22,419 | $1.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 9,764 | 8,898 | $1.12M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.5% | 6,457 | 5,891 | $293K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.8% | 9,418 | 8,066 | $236K |
| 80053 | Comprehensive metabolic panel | 2.5% | 30,678 | 26,692 | $208K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 27,158 | 23,761 | $128K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 1,992 | 1,928 | $121K |
| 97597 | 1.4% | 6,552 | 3,296 | $120K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 3,002 | 2,263 | $115K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 5,124 | 4,214 | $98K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 812 | 735 | $89K |
139 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 1,116 | $85K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,512 | $83K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,625 | $79K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,399 | $79K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 757 | $76K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,703 | $70K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,195 | $65K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,138 | $65K |
| 0240U | <1% | 667 | $63K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 554 | $62K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,446 | $62K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,040 | $59K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,216 | $59K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 509 | $57K |
| J3490 | Unclassified drugs | <1% | 16,801 | $51K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,206 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,314 | $50K |
| 81025 | <1% | 7,197 | $49K | |
| 80050 | General health panel | <1% | 1,005 | $41K |
| 80061 | Lipid panel | <1% | 3,130 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,639 | $35K |
| 83880 | <1% | 1,809 | $31K | |
| 84484 | <1% | 5,063 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 124 | $29K |
| 81001 | <1% | 13,677 | $25K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 581 | $24K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,350 | $22K |
| 74019 | <1% | 725 | $19K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 287 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 737 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 404 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 404 | $15K |
| 87088 | <1% | 2,437 | $15K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 59 | $14K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 59 | $14K |
| 85027 | <1% | 2,264 | $14K | |
| 85730 | <1% | 4,372 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 221 | $12K |
| 83690 | <1% | 2,405 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 303 | $11K |
| 85610 | <1% | 4,935 | $10K | |
| 87631 | <1% | 189 | $10K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 261 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 798 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,120 | $9K |
| 82553 | <1% | 1,438 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,372 | $7K |
| 83735 | <1% | 1,966 | $7K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 145 | $7K |
| 82550 | <1% | 1,906 | $7K | |
| 84439 | <1% | 833 | $7K | |
| 87449 | <1% | 511 | $6K | |
| 87400 | <1% | 982 | $6K | |
| 81003 | <1% | 4,299 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 109 | $5K |
| 83605 | <1% | 755 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,640 | $4K |
| 82077 | <1% | 417 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 173 | $3K |
| 96367 | <1% | 255 | $3K | |
| 82150 | <1% | 632 | $3K | |
| 87081 | <1% | 448 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 37 | $3K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,499 | $3K |
| 80320 | <1% | 764 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 369 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 912 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,054 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 61 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 111 | $2K |
| 96417 | <1% | 53 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 72 | $2K |
| 80143 | <1% | 196 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 346 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 85 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 896 | $2K |
| 84100 | <1% | 531 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 972 | $1K |
| 80179 | <1% | 117 | $1K | |
| 85651 | <1% | 296 | $1K | |
| 82728 | <1% | 120 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $1K |
| 87581 | <1% | 32 | $982.52 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,100 | $979.52 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $893.60 |
| 72100 | <1% | 39 | $851.40 | |
| 83615 | <1% | 131 | $830.86 | |
| 85007 | <1% | 404 | $791.52 | |
| 74240 | <1% | 15 | $741.40 | |
| 82785 | <1% | 41 | $736.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 41 | $694.96 |
| 86803 | <1% | 57 | $627.88 | |
| 84550 | <1% | 130 | $617.76 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 30 | $537.51 |
| 80074 | <1% | 13 | $523.93 | |
| 17250 | <1% | 45 | $508.32 | |
| 87040 | <1% | 119 | $507.01 | |
| 82607 | <1% | 45 | $497.36 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $463.75 |
| A9150 | Non-prescription drugs | <1% | 247 | $433.77 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,490 | $393.65 |
| 83540 | <1% | 93 | $354.92 | |
| 83550 | <1% | 64 | $349.60 | |
| 87077 | <1% | 63 | $312.09 | |
| 80329 | <1% | 147 | $294.67 | |
| 87070 | <1% | 77 | $250.16 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 882 | $248.21 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 28 | $211.73 |
| 90715 | <1% | 12 | $196.40 | |
| 72070 | <1% | 12 | $189.80 | |
| 84436 | <1% | 33 | $181.66 | |
| 84479 | <1% | 33 | $176.39 | |
| 87075 | <1% | 45 | $174.07 | |
| 94761 | <1% | 28 | $164.32 | |
| 86140 | <1% | 26 | $126.43 | |
| 74248 | <1% | 15 | $126.28 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15 | $119.68 |
| 87184 | <1% | 31 | $115.35 | |
| 84481 | <1% | 12 | $114.84 | |
| 80069 | <1% | 12 | $95.48 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $94.74 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 41 | $89.36 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14 | $88.77 |
| 82962 | <1% | 14 | $74.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 191 | $73.74 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 961 | $62.01 |
| 82570 | <1% | 13 | $56.98 | |
| 82270 | <1% | 14 | $38.76 | |
| 84156 | <1% | 12 | $36.70 | |
| 87205 | <1% | 12 | $21.35 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 76 | $16.34 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 120 | $16.03 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 54 | $13.61 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 22 | $0.00 |
| 02414 | 0% | 12 | $0.00 | |
| 02404 | 0% | 15 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 1,373 | $0.00 |
| A9270 | Non-covered item or service | 0% | 183 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCALLECOD, DAVID (PRESIDENT, CEO)
Parent organizationLAFAYETTE GENERAL HEALTH SYSTEM, INC.
| Provider | Location | Paid |
|---|---|---|
| University Hospital & Clinics, INC. | Lafayette, LA | $60.90M |
| ST Martin Hospital, INC. | Breaux Bridge, LA | $12.79M |
| Kaplan General Hospital, INC. | Kaplan, LA | $3.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.